Sahir Raoof, leveraging experience from SignalFire, healthcare startups, and Flatiron Health, has launched Proximal Ventures and secured $27.5 million in funding for its first solo venture capital fund. The firm’s mission: to support startups that apply artificial intelligence to transform drug development infrastructure, tools, and services. The shift aims to supercharge processes like molecular synthesis, scalable manufacturing, and trial data analysis—long outsourced by pharma firms to specialized service providers.
Why AI is Poised to Reshape Pharma Services
Historically, pharmaceutical companies haven’t been massive software buyers—they’ve leaned heavily on service providers at every stage of developing a drug. But Proximal Ventures sees AI as the lever to automate many of those manual, time-consuming steps. Automation could slash costs and accelerate drug development, allowing new entrants to compete for billions of dollars pharma typically spends on external support services.
Fund Strategy, Portfolio Moves, and Investors
Proximal is heading into the market by backing pre–seed and seed–stage companies. Initial check sizes will range between $500,000 and $1.5 million. Among its first six startup investments is ChronicleBio—co-founded by an ex-OpenAI executive, this company uses AI to interpret medical and biological data to better understand chronic illnesses and discover potential therapeutics.
Raoof’s background includes roles at SignalFire, Flatiron Health (acquired by Roche in 2018), and clinical trial startup Iterative Health. These credentials helped win over limited partners like SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and individuals such as the Dimension Capital co-founders. Also onboard is Amy Abernethy, former FDA deputy commissioner, who says Raoof’s instincts and healthcare relationships position him well to spot where the market needs innovation most.
The timing matters: first-time fund managers are facing tougher capital-raising conditions broadly. In this landscape, Proximal’s ability to pull together a strong backer base and begin deploying into high-potential AI life sciences startups signals confidence in its strategy.
Ultimately, Proximal sees its role as more than just financial backer—it aims to be a bridge between tech and pharma, spotting bottlenecks in the life sciences ecosystem and helping startups turn AI prototypes into commercially viable tools and services sooner.
What this means: drugs that might take years of manual research and incremental improvements could get accelerated by predictive modeling, automated molecular work, and smarter trial data solutions. For an industry under pressure to do more with less, that could change the rules of engagement.
